Search results - Portal of Medical Data Models (MDM-Portal)

Present aftercare Physician’s questionnaire for aftercare ABC study - Present aftercare Physician’s questionnaire for aftercare

- 9/20/21 - 1 form, 11 itemgroups, 99 items, 1 language

Itemgroups: Administrative, Medical Examination, Medical consultation, laboratory tests, Aftercare, medical consultation early cancer prevention, vaccination status, cardiovascular risk factor, Rehabilitation measures, Physical therapy, Medication

Study part: Present aftercare Physician’s questionnaire for aftercare ABC Study. Aftercare pattern in adult patients with blood cancer and blood cancer early stage: Impact on health related endpoints, quality of life and health resource use. University clinic essen, (Klinik für Hämatologie Uniklinik Essen, UKE), department hematology. Permission granted by Claudia Ose.

B. Possible late effects of disease or treatment Questionnaire for aftercare ABC study - B. Possible late effects of disease or treatment Questionnaire for aftercare

- 9/20/21 - 1 form, 20 itemgroups, 147 items, 1 language

Itemgroups: Infection, Infection, Fertility, measure Fertility, Therapy; Offspring desire, Therapy; Offspring desire, Medical Examination; Fertility problem, number of children Therapy naive, number of children therapy end, Second or other cancer diagnoses, Second or other cancer diagnoses symptom First, Medical Examination Second or other cancer diagnoses, therapy Second Primary Cancers, Cardiovascular Diseases, Cardiovascular Diseases, Medical Examination Cardiovascular Diseases, Therapy Cardiovascular Diseases, Polyneuropathy, Medical Examination Polyneuropathy, Therapy Polyneuropathy

Study part: B. Possible late effects of disease or treatment Questionnaire for aftercare ABC Study. Aftercare pattern in adult patients with blood cancer and blood cancer early stage: Impact on health related endpoints, quality of life and health resource use. University clinic essen, (Klinik für Hämatologie Uniklinik Essen, UKE), department hematology. Permission granted by Claudia Ose.

C. General health care and medical check-ups Questionnaire for aftercare ABC study - C. General health care and medical check-ups Questionnaire for aftercare

- 9/20/21 - 1 form, 6 itemgroups, 45 items, 1 language

Itemgroups: Health Care, Medical Examination Screening for cancer, Precaution cardiovascular diseases, Medical Examination Complication Diabetes Mellitus, Medical Examination Complication Hypertension, Vaccinations

Study part: C. General health care and medical check-ups Questionnaire for aftercare ABC Study. Aftercare pattern in adult patients with blood cancer and blood cancer early stage: Impact on health related endpoints, quality of life and health resource use. University clinic essen, (Klinik für Hämatologie Uniklinik Essen, UKE), department hematology. Permission granted by Claudia Ose.

GSK Ofatumumab in Waldenstrom Macroglobulinaemia, NCT00811733 - Prior WM Therapy

- 2/8/21 - 1 form, 3 itemgroups, 19 items, 1 language

Itemgroups: Administrative Data, Previous WM Treatment Status, Prior Waldenstrom's Macroglobulinemia Therapy

Study ID: 110921 Clinical Study ID: 110921 Study Title: A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00811733 Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT00811733 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Ofatumumab Trade Name: N/A Study Indication: Waldenstrom Macroglobulinaemia The primary objective of this open-label, multi-center, Phase II study was to evaluate the safety and efficacy of Ofatumumab in subjects diagnosed with Waldenstrom Macroglobulinaemia. For the study, eligible subjects were enrolled to receive up to 3 cycles of treatment with Ofatumumab. The first cycle consisted of a single dose of 300 mg followed by 3 weekly doses of 1000 mg (Treatment Group A) or 4 weekly doses of 2000 mg (Treatment Group B) of Ofatumumab, with response assessment beginning at Week 12. Based on the Week 12-16 response, eligible subjects could receive up to 2 additional cycles of treatment. This form has to be filled out at the Screening Visit.

Concomitant Medication SirTac NCT02936388 - Concomitant Medication

- 12/3/17 - 1 form, 1 itemgroup, 12 items, 1 language

Itemgroup: Concomitant Medication

Study part: Concomitant Medication. A Randomized Phase II Trial of Transarterial Radioembolisation With Yttrium-90 (SIRT) in Comparison to Transarterial Chemoembolisation With Cisplatin (TACE) in Patients With Liver Metastases From Uveal Melanoma. Provided by Prof. Dr. Ulrich Keilholz, Charité – University of medicine Berlin. EudraCT-Nummer: 2014-002439-32. NCT02936388.

End of Therapy SirTac NCT02936388 - End of Therapy

- 11/28/17 - 1 form, 1 itemgroup, 12 items, 1 language

Itemgroup: Therapy end

Study part: End of Therapy. A Randomized Phase II Trial of Transarterial Radioembolisation With Yttrium-90 (SIRT) in Comparison to Transarterial Chemoembolisation With Cisplatin (TACE) in Patients With Liver Metastases From Uveal Melanoma. Provided by Prof. Dr. Ulrich Keilholz, Charité – University of medicine Berlin. EudraCT-Nummer: 2014-002439-32. NCT02936388.

BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With AML NCT01488344 - Follow up

- 11/26/17 - 1 form, 2 itemgroups, 6 items, 1 language

Itemgroups: Follow up, investigator signature

Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML) - NCT01488344 https://clinicaltrials.gov/ct2/show/NCT01488344 Principal Investigator PD Dr. Utz Krug RATIONALE: Low-dose cytarabine works in a minority of elderly patients with an acute myeloid leukemia unfit for intensive induction therapy by killing of leukemia cells. Addition of BIBF1120 to low-dose cytarabine might enhance the killing of leukemia cells. PURPOSE: This phase I / II trial is studying how safe BIBF1120 can be combined with low-dose cytarabine (phase I) and how well the combination of low-dose cytarabine and BIBF1120 works in elderly patients with acute myeloid leukemia unfit for intensive chemotherapy (phase II). Study Type: Interventional Study Design: Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Single-arm, Open Label, Multi-center Phase I/II Trial to Assess the Safety and Efficacy of BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With AML Unfit for an Intensive Induction Therapy

E. Detailed information on the last 12 months Questionnaire for aftercare ABC study - E. Detailed information on the last 12 months Questionnaire for aftercare

- 11/23/16 - 1 form, 10 itemgroups, 115 items, 1 language

Itemgroups: occupation earnings, Level of Care, recreational activities; Self-help group support; Religious Group, Aftercare hospitalization hematologic neoplasm, Aftercare physician hematologic neoplasm, Medical Examination hematologic neoplasms, Aftercare rehabilitation measures hematologic neoplasm, Medication, Aftercare Physical therapy hematologic neoplasm, Aftercare hematologic neoplasm

Study part: E. Detailed information on the last 12 months Questionnaire for aftercare ABC Study. Aftercare pattern in adult patients with blood cancer and blood cancer early stage: Impact on health related endpoints, quality of life and health resource use. University clinic essen, (Klinik für Hämatologie Uniklinik Essen, UKE), department hematology. Permission granted by Claudia Ose.

D. Personal information and information about circumstances Questionnaire for aftercare ABC study - D. Personal information and information about circumstances Questionnaire for aftercare

- 11/21/16 - 1 form, 7 itemgroups, 62 items, 1 language

Itemgroups: Personal Information, Family history Neoplastic disease, health insurance previous, health insurance, Occupations, social contacts previous, social contacts

Study part: D. Personal information and information about circumstances Questionnaire for aftercare ABC Study. Aftercare pattern in adult patients with blood cancer and blood cancer early stage: Impact on health related endpoints, quality of life and health resource use. University clinic essen, (Klinik für Hämatologie Uniklinik Essen, UKE), department hematology. Permission granted by Claudia Ose.

A. Disease and general conditions of the aftercare Questionnaire for aftercare ABC study - A. Disease and general conditions of the aftercare Questionnaire for aftercare

- 10/26/16 - 1 form, 10 itemgroups, 85 items, 1 language

Itemgroups: therapy blood cancer, Aftercare condition, Period aftercare, Medical Examination, medical support, Supportive care, relapse blood cancer, symptoms relapse blood cancer, Medical Examination Relapse blood cancer, therapy Relapse blood cancer

Study part: A. Disease and general conditions of the aftercare Questionnaire for aftercare ABC Study. Aftercare pattern in adult patients with blood cancer and blood cancer early stage: Impact on health related endpoints, quality of life and health resource use. University clinic essen, (Klinik für Hämatologie Uniklinik Essen, UKE), department hematology. Permission granted by Claudia Ose.

General aspects Physician’s questionnaire for aftercare ABC study - General aspects Physician’s questionnaire for aftercare

- 10/24/16 - 1 form, 4 itemgroups, 45 items, 1 language

Itemgroups: Administrative, Comorbidity, Aftercare, Aftercare importance

Study part: General aspects Physician’s questionnaire for aftercare ABC Study. Aftercare pattern in adult patients with blood cancer and blood cancer early stage: Impact on health related endpoints, quality of life and health resource use. University clinic essen, (Klinik für Hämatologie Uniklinik Essen, UKE), department hematology. Permission granted by Claudia Ose.

Dose-Limiting Toxicity LeMLAR-Studie Lymphoma NCT01788189 - Dose-Limiting Toxicity (only cycle 1 and 2)

- 9/28/16 - 1 form, 1 itemgroup, 31 items, 1 language

Itemgroup: Dosage

Study part: Dose-Limiting Toxicity LeMLAR-Studie. Lenalidomide in conjunction with methotrexate, leucovorin, cytarabine and rituximab for the treatment of relapsed or refractory CD20-positive aggressive lymphomas: an open-label, multicenter phase I/II trial. Publication granted by Prof. Dührsen and provided by Claudia Ose, University clinic Essen, NCT01788189, Version 1.3-28.04.2013.doc.

Keywords

Table of contents

Selected data models